Moreover, DUSP6 level was reduced already after short treatment of melanoma cells with either vemurafenib or trametinib, which further supports the notion that DUSP6 suppression might not be essential for the development of resistance to targeted therapeutic. The gene discussed is DUSP6; the disease is melanoma.